Back to News
Mergers & Acquisitions

Drinks With The Deal: Sullivan & Cromwell’s Frank Aquila

Published: June 22nd, 2020
Sullivan’s head of M&A talks to The Deal's David Marcus about his recent work for Tiffany’s, Novartis and Amgen, the challenges consumer goods companies face, and his favorite bars in Hong Kong, Tokyo and New York.

Last fall’s sale of Tiffany’s Inc. (TIF) was perhaps the most-widely covered M&A transaction of 2019, as media of all sorts covered LVMH Moet Hennessy Louis Vuitton SE’s hostile bid for the jewelry retailer and its ultimately success deal to sell  to the luxury goods company for $16.2 billion.

But Frank Aquila, the Sullivan & Cromwell LLP partner who advised the target, told its directors to ignore the coverage and focus on achieving the best result for the company, as he discusses with The Deal’s David Marcus on the latest Drinks With The Deal podcast.

Aquila also talks about his work on two other large pharma deals last year. Sullivan’s head of M&A advised longtime client AmGen Inc. (AMGN) on its purchase of Otezla, a treatment for psoriasis and psoriatic arthritis, for $13.4 billion from Celgene Corp. (CELG) as part of its sale to Bristol-Myers-Squibb Co. (BMY) and Novartis AG on its $9.7 billion purchase of Medicines Co.

Aquila has done work for many years for Diageo plc and Anheuser-Busch InBev SA/NV (BUD), which he represented last fall on its $221 million purchase of Craft Brew Alliance Inc., and discusses the changing market that consumer goods companies face.

A food and wine aficionado in his spare time, Aquila enjoys searching out distinctive spots around the globe, from Angel’s Share, Brandy Library and Don Angie in Manhattan to The Old Man in Hong Kong and Bar Orchard in Tokyo.

More podcasts from The Deal are available on iTunesSpotify and SoundCloud and on


More From Mergers & Acquisitions

Mergers & Acquisitions

Zoetis' Nayak Talks Animal Health Trends Amid Covid

By Armie Margaret Lee
Published: July 7th, 2020
Trends such as the humanization of pets have accelerated amid the Covid-19 crisis, said Abhay Nayak, head of global strategy, commercial development and customer experience at Zoetis.